Cartilage Injury and Regeneration Research

For a cartilage defect, assess subchondral bone, surrounding cartilage and meniscus, alignment, and ligament stability as well as depth and area. Restoring a focal defect and treating widespread arthritis have different aims.

Outerbridge and ICRS classifications describe lesions. Symptoms, compartment, loading, and associated pathology are also needed when comparing treatment conditions.

For a focal cartilage defect, describe depth, size, location, containment, and subchondral bone status. Outerbridge or ICRS grading standardizes the description of injury but does not explain the patient's symptoms or recovery potential. OCD and osteochondral lesions require assessment of fragment stability, bone viability, and growth plates and should not be placed in the same algorithm as a defect limited to the cartilage surface.

Before planning restoration, assess malalignment, meniscal deficiency, ligament instability, and surrounding degeneration. Filling a focal defect does not remove the different treatment conditions of a persistently overloaded or unstable joint. Do not assign a technique on defect area alone; integrate bone injury, activity goals, previous surgery, and rehabilitation feasibility. Explain that extensive OA and a focal defect pose different treatment questions.

Microfracture, OAT/OCA, and ACI/MACI differ in the tissue and bone they aim to restore, their cells or scaffolds, and their surgical stages. Compare indications in the context of the defect, joint environment, and rehabilitation.

Histology, defect filling on MRI, and patient-reported pain and function are different outcomes. A cellular or biological mechanism does not itself establish clinical efficacy. Approval, availability, and actual indications require confirmation for each country and product.

Microfracture induces marrow-derived repair, OAT and OCA transfer osteochondral tissue, and ACI and MACI attempt cell-based restoration. These techniques differ in subchondral bone treatment, donor-site morbidity, tissue procurement, and surgical stages. Defect-size thresholds and durability findings should not be applied unchanged to every product and lesion. Check the patient population, definition of failure, concomitant correction, and follow-up duration.

Assess defect fill and tissue properties separately from pain, function, return to activity, reoperation, and joint preservation. MRI fill should not be assumed to provide the mechanical function of normal hyaline cartilage. Also distinguish experimental mechanisms of cells, scaffolds, and biological agents from clinical effects in humans and regulatory approval for use. Rehabilitation loading restrictions should be matched to lesion location and size, fixation, and concomitant surgery.

Marrow stimulation uses microfracture or drilling to access marrow beneath the subchondral plate and induce defect repair. Marrow elements and clot contribute to repair-tissue formation, but restoration of the structure and mechanics of native hyaline cartilage is not guaranteed. Consider it for relatively small focal full-thickness defects while evaluating healthy surrounding cartilage walls, lesion location, and bone status. Confirm that symptoms arise from the lesion, and do not assign extensive degenerative osteoarthritis the same indication.

Select treatment using age, activity demands, symptom duration, meniscal deficiency, ligament instability, and the load axis alongside area. Uncontained defects that cannot retain a marrow clot and substantial bone defects may require another restoration strategy. Previous marrow stimulation, bony overgrowth, and cysts influence later surgical planning. Explain the convenience of a relatively simple single-stage procedure together with variable long-term function and the subchondral changes relevant to subsequent treatment.

Prepare stable surrounding cartilage walls after removing unstable tissue while avoiding excessive subchondral-bone removal. Perforation depth, spacing, and instruments affect marrow access and plate injury, so document the technique. Experimental studies observed different bony responses to drilling and an awl, but a particular depth from an animal model should not be transferred directly to humans. Progress postoperative loading according to lesion location, size, and accompanying procedures, while following pain, effusion, and motion.

Selected traumatic-defect cohorts reported sustained symptom improvement, but comparative-trial outcomes and failure rates varied with population and lesion characteristics. Assess defect fill, pain and function, and reoperation separately. Bony overgrowth was associated with failure in some clinical studies, but imaging alone cannot establish the cause of symptoms. Improvement after focal cartilage treatment does not guarantee prevention of osteoarthritis progression or avoidance of arthroplasty.

Osteochondral transplantation transfers cartilage and underlying bone together to reconstruct a focal defect. For lesions with subchondral loss or damage to the osteochondral unit, it addresses a different problem from filling only the surface. OAT uses autologous tissue and OCA uses donor tissue. Record area, depth, location, surrounding cartilage, osteonecrosis, OCD, and previous surgery, and establish that the lesion corresponds to symptoms before selecting treatment.

OAT can transfer viable osteochondral plugs in a single stage, but available tissue and donor-surface curvature are limited. With multiple plugs in mosaicplasty, consider individual height, intervening spaces, and continuity of the articular surface. Calling a donor region “nonweight-bearing” does not eliminate the possibility of pain or mechanical symptoms. Weigh the benefit for a small focal lesion against donor-site burden, and critically examine plans to continually increase plug number for a large lesion.

OCA can reconstruct large or deep defects without autograft harvesting, but tissue availability, size and curvature matching, and preservation conditions matter. Prepare the recipient site with adequate bone depth and healthy support, and minimize surface steps and tilt. Bone integration and survival of the cartilage tissue are distinct assessments. Associations between storage duration and outcomes depend on preservation methods and patient selection; a date from one study is not a universal tissue-use criterion.

Before transplantation, assess malalignment, meniscal deficiency, and instability and plan unloading or stabilization when needed. Trials and cohorts of selected patients reported improved function and graft survival, but different OAT and OCA populations make simple success-rate comparisons difficult. Follow bone integration, subsidence, graft interfaces, pain and function, and further surgery separately. Match loading to fixation, bony incorporation, lesion location, and accompanying procedures; graft survival is not equivalent to full return to previous activity.

ACI and MACI use autologous chondrocytes to restore focal cartilage defects. Tissue is harvested, cells are cultured, and implantation follows; membrane or matrix composition and fixation differ among techniques. Cell acquisition, subchondral-bone handling, and staging differ from marrow stimulation. The shared term “cells” does not justify transferring the same clinical effects to other cell products or injections. First confirm that the defect corresponds to symptoms.

Selection includes defect area, depth, surrounding walls, subchondral bone, and the overall joint environment. Treatment may be considered for larger focal defects, but extensive osteoarthritis is a different treatment population. With substantial bone injury, first plan the relationship to bone reconstruction or osteochondral transplantation. Assess alignment, meniscal status, ligaments, and patellofemoral tracking, and account for previous surgery and the patient's ability to complete staged treatment and rehabilitation. Area alone does not assign cell-based treatment.

In the SUMMIT randomized trial of symptomatic defects of at least 3 cm², MACI provided better pain and function outcomes than microfracture at 5 years, while the between-group difference in MRI fill was not significant. Favorable long-term prospective cohorts should be distinguished from evidence of superiority over a comparator. A recent randomized trial in patients with failed previous treatment reported both improved 10-year function with ACI and similar treatment-failure rates. Read population, technique generation, comparator, and endpoint together.

Assess pain, daily activities, sporting function, graft condition, and reoperation separately. Improved tissue fill or imaging scores alone do not establish native hyaline-cartilage mechanics or long-term osteoarthritis prevention. Evaluate hypertrophy, delamination or incomplete integration, and persistent pain separately, and investigate other causes when appropriate. Progress loading and flexion according to defect location, fixation, accompanying procedures, and recovery. Prognostic discussions should combine potential clinical improvement with staged-treatment burden and the possibility of further surgery.

Osteochondritis dissecans (OCD) assessment includes subchondral bone and osteochondral fragment stability as well as the cartilage surface. Juvenile status follows an open growth plate rather than a fixed age. Activity-related pain and swelling are distinguished from locking and catching; bilateral symptoms and lesion location are checked rather than attributing everything to anterior knee pain.

After a lesion is identified on radiographs, MRI characterizes its size, cartilage surface, underlying bone and associated meniscal or ligament injury. The 2023 AAOS guideline rates MRI evidence highly for characterizing known OCD, but a single signal finding does not determine surgical fragment stability in every case. Developmental signal changes are distinguished from actual instability, with mechanical symptoms compared against serial imaging.

A stable lesion with open growth plates can be protected with activity modification and monitored for healing. In a 2008 prospective study, approximately two-thirds of stable juvenile lesions progressed toward healing over six months; larger lesions, swelling and mechanical symptoms were unfavorable factors. This is not an individual probability of complete recovery. Protection and return-to-activity planning follow changes in pain, swelling and imaging evidence of reossification.

Surgery can be offered for symptomatic unstable or displaced lesions regardless of growth-plate status, with AAOS explicitly noting limited evidence for this recommendation. Drilling for a stable lesion that fails to heal with nonoperative care is distinguished from fixation of a salvageable unstable fragment and restoration of an unsalvageable defect. Fragment excision is distinguished from articular-surface preservation, and outcomes are assessed separately as healing, surface status, symptoms and reoperation.